Report
Nyxoah - New partnership with ResMed in Germany
Nyxoah announced it has entered into a partnership with first-line treatment player ResMed to increase awareness about OSA and educate patients about the different treatment options. Beyond the fact that this partnership will beneficiate Nyxoah by helping to raise awareness about OSA which remains highly under-diagnosed, we deem this partnership to be interesting as it again shows the interest from first line treatment player in HGNS. Remember that we consider that Nyxoah could become an attractive acquisition target, should results from the DREAM trial – expected around March 2024 – come out positive. In our view, potential acquirers include companies
Underlying
Nyxoah
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Laura Roba
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.